Choksi Laboratories net profit up 51% in Q1FY27 to ₹58.24 lakh
Choksi Laboratories posted a 51% YoY jump in net profit to ₹58.24 lakh for Q1FY27, aided by significant tax credits. Revenue grew 7% to ₹1,207.89 lakh, while PBT dipped 4.5% due to rising expenses. The board also approved key governance changes.
*this image is generated using AI for illustrative purposes only.
Choksi Laboratories reported a net profit of ₹58.24 lakh for the quarter ended June 30, 2026, rising 51% from ₹38.50 lakh in the same period last year. Total revenue from operations increased 7% year-on-year to ₹1,207.89 lakh, up from ₹1,124.52 lakh in Q1FY25.
The company’s Board of Directors approved the unaudited financial results on August 13, 2026. The results were reviewed by Prateek Jain & Co., who issued a limited review report with no qualifications. The financials were prepared in accordance with Ind AS 34 and SEBI LODR regulations.
Financial Performance
Revenue from operations stood at ₹1,206.29 lakh, compared to ₹1,124.19 lakh in the corresponding quarter of FY25. Other operating revenue contributed ₹1.60 lakh. Total expenses were ₹1,147.96 lakh, leading to an operating profit before tax of ₹59.93 lakh.
| Metric: | Q1FY26 (₹ in Lakhs) | Q1FY25 (₹ in Lakhs) | Change: |
|---|---|---|---|
| Revenue from Operations: | 1,206.29 | 1,124.19 | +7.3% |
| Total Revenue: | 1,207.89 | 1,124.52 | +7.4% |
| Total Expenses: | 1,147.96 | 1,061.78 | +8.1% |
| Profit Before Tax: | 59.93 | 62.74 | -4.5% |
| Net Profit: | 58.24 | 38.50 | +51.3% |
Earnings per share (basic and diluted) were ₹0.84, compared to ₹0.55 in the previous year’s corresponding quarter. For the full fiscal year ended March 31, 2026, the company reported total revenue of ₹4,621.93 lakh and a net profit of ₹196.43 lakh.
What the Numbers Show
While profit before tax declined slightly by 4.5% to ₹59.93 lakh due to higher operating expenses, the net profit surged 51% year-on-year. This divergence is primarily driven by favorable tax adjustments. Deferred tax expenses showed a credit of ₹16.30 lakh in Q1FY26, compared to a debit of ₹12.43 lakh in Q1FY25. Additionally, mat credit utilization resulted in a benefit of ₹8.54 lakh, contrasting with a charge of ₹1.88 lakh in the prior year. These tax-related items significantly boosted the bottom line despite modest operational profitability.
Corporate Actions
The Board approved several administrative and governance measures:
- Re-appointed Ms. Himika Choksi as Whole Time Director for five years, effective April 1, 2027, subject to shareholder approval.
- Scheduled the 33rd Annual General Meeting for September 18, 2026, via video conferencing.
- Set the register closure period from September 12 to September 18, 2026.
- Re-appointed M/s Tanmay V. Rajurkar & Co. as Internal Auditor for FY27.
- Changed the Registrar and Share Transfer Agent from MUFG Intime India Private Limited to Ankit Consultancy Private Limited.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE493D01013/e761f0f8-8675-45ef-b4b5-c3be05550cc4.pdf
Historical Stock Returns for Choksi Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.55% | -4.80% | -1.71% | -2.32% | -45.37% | +497.22% |
Will Choksi Laboratories be able to sustain the 51% net profit growth in upcoming quarters without relying on favorable tax adjustments and MAT credit benefits?
How does the 8.1% rise in total expenses compare to industry peers, and what specific cost-control measures are planned to improve operating margins?
What is the strategic rationale behind switching the Registrar and Share Transfer Agent to Ankit Consultancy Private Limited, and will this impact shareholder services?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
